Dengue fever in patients with multiple sclerosis taking fingolimod or natalizumab.

Abstract

Dengue fever is the most prevalent mosquito-borne viral illness in humans. There may be different clinical manifestations of the disease, from mild symptoms to hemorrhagic forms of dengue fever and even neurological complications of this viral infection. Blood cells are usually affected, and thrombocytopenia is the hallmark of the disease. This paper presents 15 cases of dengue fever in patients with multiple sclerosis (MS) taking fingolimod or natalizumab. There were no complications of dengue fever or worse outcomes of MS in these patients, and only four of them needed short-term treatment withdrawal due to lymphopenia.

DOI: 10.1016/j.msard.2016.01.005

Cite this paper

@article{Fragoso2016DengueFI, title={Dengue fever in patients with multiple sclerosis taking fingolimod or natalizumab.}, author={Y{\'a}ra Dadalti Fragoso and Paulo Diniz da Gama and Sidney Gomes and Jussara Mathias Netto Khouri and Andr{\'e} Palma da Cunha Matta and Maria Fernanda Mendes and Carla Renata Aparecida Vieira Stella}, journal={Multiple sclerosis and related disorders}, year={2016}, volume={6}, pages={64-5} }